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 It is well recognized that, similar to other 
pathophysiological events, sepsis evokes a 
balance of both pro- and anti-infl ammatory 
responses, which include release of 
cytokines into circulation. An unregulated 
and overwhelming response in the presence 
of severe sepsis is associated with negative 
outcomes. Although certain cytokines 
(such as tumor necrosis factor-  , inter-
leukin-6, interleukin-1  , and HMGB-1) 
have been commonly studied and have 
been suggested to play a prominent role, 1,2 
no single cytokine or group of cytokines has 
been identifi ed as having a pivotal role in 
pathogenesis. Perhaps not surprisingly, 
prior studies concentrating on interruption 
of a single cytokine / system have failed to 
show outcome benefi ts despite promising 
animal data. 3,4 Ronco  et al. 5 have addressed 
this by proposing a  ‘ peak concentration 
hypothesis, ’ which suggests that supra-high 
concentrations of a variety of cytokines, 
beyond the level needed to upregulate 
immunity, play an important role in the 
causality of the syndrome itself. However, 
studies based on this concept, using extra-
corporeal therapies (ECTs) intended 
to nonspecifically remove a variety of 
low- and middle-molecular substances 
including cytokines to blunt the high peaks 
in concentrations, have produced confl ict-
ing results. 4 
 Peng  et al. 6 (this issue) now describe their 
study with a synthetic polymer-based 
cytokine adsorbent system, CytoSorb, 
aimed at removal of a broad panel of 
cytokines in a mouse model of sepsis cre-
ated by cecal ligation and puncture (CLP) 
technique. Th eir prior study with the same 
system and model demonstrated an ability 
to reduce cytokine levels and improve out-
comes. 6 Th e current study was designed 
to test the CytoSorb therapy without sig-
nifi cantly reducing the cytokine levels (in 
eff ect either negating the peak or remov-
ing alternate substances) in a less severe 
model of sepsis (to achieve a higher 7-day 
survival). Th e authors included cytokines 
commonly considered to be involved in 
the process of sepsis and to have strong 
outcome associations. ECT with CytoSorb 
did not alter post-therapy cytokine levels 
but instead demonstrated a reduction in 
late (48 – 72  h) rise in measured cytokine 
levels and cellular responsiveness as 
refl ected by nuclear factor-  B (NF-  B) 
activity in circulating polymorphonuclear 
cells. Additionally, the authors show a 
reduction in new organ damage as 
refl ected by biochemical and pathological 
parameters and improved 7-day survival. 
 The study has several strengths. The 
authors paid careful attention to the crea-
tion of a controlled CLP model to extend 
survival so that the eff ects of ECT could be 
evaluated, and deliberately delayed the 
initiation of therapy to allow the onset of 
sepsis (both adjustments were made to 
more closely emulate clinical human sep-
sis). The control, sham, and exchange 
transfusion models allowed testing in a 
graded manner. Th e outcome parameters 
were physiologically relevant with a good 
selection of biomarkers, refl ecting a good 
estimate of our current understanding of 
both the pro- and the anti-infl ammatory 
arms, 1,2 coupled with indices for organ 
damage and survival. 
 However, several important issues need 
to be considered. Th e authors attempted to 
test the eff ects of CytoSorb therapy without 
much aff ecting the measured cytokine lev-
els to understand the relative importance 
of these cytokines in the pathophysiology 
and outcomes. However, a complete lack 
of change in measured cytokine levels by a 
therapy that is effi  cient in removal of these 
substances, both within the group receiv-
ing ECT and in comparison with control 
and sham animals, is surprising. Addition-
ally, the conclusion that the change in the 
measured cytokines does not explain the 
outcomes cannot be drawn, as the hard 
end points, for example, organ damage and 
survival, were well preceded by lowered 
levels of measured cytokines at 48 – 72  h. It 
thus appears that the events upstream of 
these cytokines are aff ected by the therapy, 
though its relative signifi cance cannot be 
judged. Studying a subset of mice ( n  =  14), 
the authors showed that these eff ects might 
be related to inhibition of NF-  B activity, 
which was ascribed to the adsorption ther-
apy itself, though it is unclear from the 
available data how the proposed reduction 
in the intracellular activity of NF-  B cor-
relates with the extracellular blood purifi -
cation. Pathways upstream of the NF-  B 
activation, active earlier in the pathogen-
esis of sepsis, were not examined in the 
study, and a closer look could have pro-
vided insight into the critical aspects of 
pathophysiology. It is also unlikely that all 
immune-suppressive signals are benefi cial 
to the outcomes. NF-  B is crucial for the 
regulation of immune responses and con-
trol of infections, and a defect in NF-  B 
action has been linked to a higher predis-
position toward severe systemic  infections. 7 
In the end, despite substantial similarities 
between the CLP model and human 
 Extracorporeal therapy in sepsis: 
are we there yet ? 
 Ashutosh M.  Shukla 1 
 The role of extracorporeal therapies (ECTs) in sepsis is unclear 
and is a strongly debated topic in critical-care medicine. Unfortunately, 
much of this debate arises because we lack a clear understanding of 
what defines the stage and severity of the disease, and the pivotal 
pathophysiological events dictating outcomes. In the absence of this 
knowledge, ECTs remain among a large group of therapies with high 
promise but unproven efficacy. 
 Kidney International (2011)  81, 336 – 338.  doi: 10.1038/ki.2011.375 
 1 Division of Nephrology, University of Arkansas for 
Medical Sciences ,  Little Rock ,  Arkansas ,  USA  
 Correspondence: Ashutosh M. Shukla, 
Division of Nephrology, University of Arkansas 
for Medical Sciences, 4301 W. Markham Street 
Slot 501, Little Rock, Arkansas 72205, USA. 
E-mail:  amshukla@uams.edu 
commentar y
Kidney International (2012) 81     337
sepsis, it is recognized that there are sig-
nifi cant diff erences between these two 
models of sepsis. Multiple therapies found 
highly effi  cacious in animal models have 
failed in human sepsis studies. Th e com-
plexities of the immune system, diff er-
ences in the model of sepsis and its 
microbial constitution, intervention strat-
egies employed earlier in the sepsis, and 
the presence of comorbidities have been 
argued as some of the explanations for 
these heterogeneities. 8 
 Additional considerations must include 
whether the study by Peng  et al. 6 can be 
reconciled with our existing knowledge of 
the pathophysiology of sepsis and our 
prior experiences with ECTs in animal 
and human sepsis . Th eir study suggests 
a potential benefi t with early-stage inter-
vention for the management of sepsis. 
Th is, however, has previously been tested 
in a variety of manners. Interventions ear-
lier in the genesis of sepsis focusing on 
isolated pathophysiological targets such 
as anti-endotoxin antibodies, anticytokine 
therapy, anticoagulant therapy, and so on 
have failed to show any benefi ts in clinical 
outcomes. 3,4 Th is has resulted in a shift  of 
the focus toward removal of a multitude 
of cytokines, principally through ECTs 
such as hemofi ltration, with the intent of 
reducing their peak concentrations 
 en masse . Hemofi ltration is effi  cient in 
removal of a variety of cytokines through 
a combination of adsorption and convec-
tion 4,9 and has shown promising results in 
animal models. However, its use in human 
sepsis without acute kidney injury has 
shown limited benefi ts, mainly in improv-
ing soft  clinical end points such as oxy-
genation, vasopressor use, and so on. 10 
Th e largest human randomized control-
led trial with early intervention using 
conventional hemofi ltration in patients 
with sepsis without acute kidney injury 
not only failed to demonstrate any 
benefi t but showed an association with 
worsening outcomes and a higher sever-
ity and number of organ damage scores. 11 
Th ese disappointing results with conven-
tional hemofi ltration have led some to 
suggest that perhaps a higher volume of 
hemofi ltration therapy might lead to even 
better cytokine clearance and perhaps 
improvement in outcomes. 12,13 Unfortu-
nately, though, this remains specu lative 
at present, especially since our parallel 
experiences with ECT dosing in the man-
agement of acute kidney injury in sepsis 
have repeatedly failed to show a signifi -
cant clinical benefi t with an increasing 
dose of therapy 14 and do not have wide-
spread support. 
 Considering these confusing and some-
times quite contradictory results, the 
larger question remains: Is there promise 
for ECT in the management of sepsis? 
Th is of course will depend on defi ning the 
pivotal pathophysiological mechanism or 
mechanisms critical to the genesis of the 
syndrome; the properties of the cytokines 
or substances to be altered and their kinet-
ics; and the severity and the stage of illness 
at which the intervention is needed and is 
to be stopped. Sepsis needs both a strong 
infl ammatory phase for the physiological 
clearance of infective insults ( Figure 1 , 
area A) and presumably a counteractive /
 protective anti-inflammatory phase 
for immune reconstitution and recovery 
( Figure 1 , area C). Th e goal at present is to 
counter the systemic adverse infl uence of 
the cytokine storm, which is dispropor-
tionate and counterproductive ( Figure 1 , 
area B). Apart from the lack of a clear 
target or targets for removal, we have a 
limited understanding for determining 
the severity and immune stage of sepsis. 
An intervention in either the adaptive 
infl ammatory or the immune-recovering 
anti-infl ammatory phase might do more 
harm than good in these instances. Iden-
tification of the precise mechanism 
through which the benefi ts of ECTs accrue 
can obviate some of the above-mentioned 
concerns and may allow examination of 
those axes in human sepsis. In this regard, 
the study by Peng  et al. 6 is signifi cant and 
provides us with directions to probe fur-
ther upstream of the NF-  B pathways to 
precisely understand the physiological 
mechanisms responsible for the adverse 
outcomes. On similar grounds, Cruz  et al. , 
using a polymyxin B-coated hemofi ltra-
tion designed to remove endotoxin and 
thus intervening at an earlier stage of sep-
sis, recently showed not only an improve-
ment in vasomotor tone but a signifi cant 
survival advantage. 15 Noteworthy is the 
fact that this human randomized study 
was also done in a setting of intra-abdom-
inal sepsis that is pathophysiologically 
analogous to the CLP model and may 
indicate the importance of early events in 
such models of sepsis. 
 In summary, the study by Peng 
 et al. 6 advances the fi eld as it attempts to 
raise concerns regarding a purely acute 
 ‘ cytokinecentric ’ approach toward devel-
oping new therapies for sepsis by examin-
ing the commonly measured cytokines, 
and indicates a role for potentially critical 
events upstream of NF-  B activation early 
in the genesis of sepsis. However, it fails to 
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 Figure 1  |  Theoretical considerations of the likely impact of ECT in a single-hit model of 
sepsis, and its correlation to the stage and severity of disease. ECT, extracorporeal therapy. 
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isolate these precise upstream mechanisms 
responsible for the reported benefi t. Over-
all, it hints at a future potential for 
adsorption / CytoSorb therapy in the man-
agement of sepsis, although this will 
require a better defi nition of the critical 
pathophysiological mechanisms, with a 
closer look at events early in the genesis of 
sepsis. Until we resolve some of these key 
issues, the role of ECTs in the management 
of sepsis will continue to be debated. 
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 Renal failure during Gram-negative 
sepsis can be profound, diffi  cult to treat, 
and fatal. 1,2 It occurs in a well-known set-
ting of endotoxemia, endotoxin binding 
to endothelium and leukocytes, produc-
tion and release of cytokines, and a sys-
temic  ‘ cytokine storm ’ accompanied by 
decreased peripheral vascular resistance 
and hypotension — septic shock. In light 
of the dire systemic disturbance, a puz-
zling aspect of acute kidney injury (AKI) 
in sepsis is the paucity of structural renal 
damage despite severely impaired func-
tion. 2,3 Although the glomerular fi ltration 
rate (GFR) can decrease during septic AKI 
as a consequence of generalized circula-
tory collapse and attendant reduction of 
renal blood fl ow (RBF), 1 kidney-specifi c 
factors have important roles as well and 
may dominate. Renal events that deter-
mine septic AKI have been examined in 
animal models. 3,4 When the macrocircu-
lation fails, RBF and GFR decrease, but 
these hallmarks of AKI are also evident in 
normotensive models of murine endotox-
emia. 1,3,5 Moreover, persistent azotemia 
develops in sheep injected with live 
 Escherichia coli despite increased RBF. 3 
Along these lines, early volume replace-
ment can restore GFR in some models, 
whereas in other situations, it only allows 
AKI to be expressed, by delaying death 
due to systemic sepsis. 3 Thus, kidney 
injury seems likely during sepsis. Never-
theless, as stated earlier, overt structural 
damage of the kidney is uncommon in 
septic AKI, 2 and the best-documented 
lesion is subtle vacuolation of tubule epi-
thelium, 3 a pathology that has not received 
rigorous investigative attention. On the 
other hand, we know that renal damage in 
experimental septic AKI is potentially 
reversible, at least by inference from the 
benefi ts aff orded by early interventions 
that restore renal function. Such inter-
ventions include volume replacement, 
renal denervation, free radical scavengers, 
and anti-inflammatory therapies. 1,3,5 
Although these modalities could work 
entirely through their eff ects on systemic 
 hemodynamics or the renal circulation, 
equally plausible arguments could be 
mounted for the primacy of a tubular 
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 Oxidant stress and compromised microcirculation underlie renal 
pathophysiology in septic acute kidney injury (AKI). Holthoff  et al . 
report that resveratrol ameliorates these coupled abnormalities. 
They did not establish the primacy of either defect in septic AKI. 
However, tubule mitochondrial defects were recently reported to be 
involved in septic AKI pathogenesis, and resveratrol targets PGC-1  
and respiratory enzymes. Together, these findings open new avenues 
for research into long-unresolved issues in the pathophysiology of 
septic AKI. 
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